ArticleEndocrine2025
Growth plate continuity on knee MRI predicts growth hormone effect in mid-to-late puberty with idiopathic short stature.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo evaluate the efficacy and cost-effectiveness of recombinant human growth hormone (rhGH) therapy in adolescents with idiopathic short stature during mid-to-late puberty, using knee MRI to predict therapeutic response.
methodsThis one-year prospective cohort study included 50 idiopathic short stature adolescents and 100 healthy controls. Participants underwent knee MRI to classify growth plates into "continuous" and "discontinuous" subgroups. Growth response to growth hormone was measured through height and height standard deviation score changes, while cost-effectiveness was assessed using cumulative growth hormone dose and growth outcomes. Kaplan-Meier analysis was performed to evaluate therapy response, and linear mixed models analyzed height growth differences.
resultsAfter one year, the treatment group showed significant height gains (6.08 ± 2.73 cm) compared to controls (3.91 ± 2.70 cm; P < 0.001). Subgroup analysis revealed that adolescents with continuous growth plates at proximal tibia exhibited greater height improvements (ΔHtSDS = 0.92 ± 0.37) than those with discontinuous plates (ΔHtSDS = 0.73 ± 0.49; P = 0.016); subgroups categorized by distal femur achieved ΔHtSDS 0.91 ± 0.44 and 0.56 ± 0.29, respectively (P = 0.004). Cost-effectiveness was higher in the continuous growth plate subgroup, requiring lower rhGH doses per centimeter of growth.
conclusionsKnee MRI classification of growth plate continuity is a reliable predictor of rhGH therapy response and cost-effectiveness in mid-to-late pubertal adolescents with idiopathic short stature. Continuous growth plates correlate with better treatment outcomes and more favorable cost-effectiveness, emphasizing the importance of early intervention for optimal results.
Indexed as
Identifiers
40864383What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.